Animal models of negative symptoms: M100907 antagonizes PCP-inducedimmobility in a forced swim test in mice

Neuropsychopharmacology

Volumn 21, Issue 6, 1999, Pages S211-S218

  Corbett, Roy ^a   Zhou, Lily ^a   Sorensen, Stephen M ^a   Mondadori, Cesare ^a  

^a SANOFI   (France)

Author keywords

907; Animal models; M100907; MDL 100; Negative symptoms; Schizophrenia; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; HALOPERIDOL; PHENCYCLIDINE; SEROTONIN 2A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SWIMMING;

EID: 0032785064     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00128-1     Document Type: Article

References (48)

1. Aghajanian GK, Marek GJ (1997): Serotonin induces excita-tory postsynaptic potentials in apical dendrites of neo-cortical pyramidal cells. Neuropsychopharmacology 36:589-599
2. American Psychiatric Association (1997): Practice guidelines for the treatment of patients with schizophrenia. Am JPsychiatry 154:1-50
3. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D(1997): Association of ketamine-induced psychosis withfocal activation of the prefrontal cortex in healthy vol-unteers. Am J Psychiatry 154:805-811
4. Carlsson ML (1995): The selective 5-HT2Areceptor antagonist MDL 100, 907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in themouse—implications for psychosis. J Neural Transm100:225-237
5. Collaborative Working Group on Clinical Trial Evaluations (1998): Assessing the effects of atypical antipsychoticson negative symptoms. J Clin Psychiatry 59(Suppl12):28-34
6. Corbett R, Hartman H, Kerman LL, Woods AT, Strupczew-ski JT, Helsley GC, Conway PC, Dun RW (1993): Effects of atypical antipsychotic agents on social behavior inrodents. PharmacolBiochemBehav 45:9-17
7. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995): Antipsychotic agents antag-onize non-competitive N-methyl-d-aspartate antago-nist-induced behaviors. Psychopharmacology 120:67-74
8. Duinkerke SJ, Botter PA, Jansen AAI, Van Dongen PAM,Van Haaften AJ, Boom AJ, Van Laarhoven JHM, Busard HLM (1993): Ritanserin, a selective 5-HT2/1Cantagonistand negative symptoms in schizophrenia. Br J Psychiatry 163:451-455
9. Ellenbroek BA, Willemen APM, Cools AR (1989): Are antag-onists of the dopamine D1receptors, drugs that attenu-ate both positive and negative symptoms of schizophrenia? A pilot study in Jave monkeys.Neuropsychopharmacology 2:191-199
10. Hamada S, Senzaki K, Hamaguchi-Hamada K, Tabuchi K, Yamamoto H, Yamamoto T, Yoshikawa S, Okano H, Okado N (1998): Localization of 5-HT2A receptor in ratcerebral cortex and olfactory system revealed by immu-nohistochemistry using two antibodies raised in rabbitand chicken. Mol Brain Res 54:199-211
11. Hayashi T, Yokota N, Takahashiu T, Tawara Y, Nishikawa T, Yano T, Furutani M, Fugikawa T, Horguchi J, Yamawaki S (1997): Benefits of trazodone andmianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: An add-on double-blindplacebo controlled study. IntClinPsychopharmacol12:199-205
12. Hertzman M, Reba RC, Kothyarove EV (1990): Single photon emission computerized tomography in phencyclidineand related drug abuse. Am J Psychiatry 147:255-256
13. Hitchcock JM, Grauffel CA (1996): Comparison of the 5-HT2Aantagonist MDL 100, 907 with typical and atypical antip-sychotics in phencyclidine and amphetamine-stimu-lated locomotion tests in mice. Schizophr Res 18:141
14. Iskedjian M, Remington GJ (1998): The Canadian experience with risperidone for the treatment of schizophrenia: Anoverview. J Psychiatry Neurosci 23:229-239
15. Jakab RL, Goldman-Rakic PS (1998): 5-Hydroxtryptamine2A serotonin receptors in the primate cerebral cortex: Pos-sible site of action of hallucinogenic and antipsychoticdrugs in pyramidal cell apical dendrites. ProcNatlAcadSci USA 95:735-740
16. Javitt DC, Zukin SR (1991): Recent advances in the phency-clidine model of schizophrenia. Am J Psychiatry 148:1301-1308
17. Kane J, Honigfeld G, Singer J, Meltzer HY (1988): Clozapine for the treatment-resistant schizophrenic. Arch GenPsychiatry 45:789-796
18. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, Van Giersbergen PLM, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996): Preclinical characterizationof the potential of the putative atypical antipsychoticMDL 100, 907 as a potent 5-HT2Aantagonist with afavorable CNS safety profile. J Pharm ExpTher277:968-981
19. Kelley ME, van Kammen DP, Allen DN (1999): Empirical validation of primary negative symptoms: Indepen-dence from effects of medication and psychosis. Am JPsychiatry 156:406-411
20. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS(1994): Subanesthetic effects of the noncompetitiveNMDA antagonist, ketamine, in humans. Psychotomi-metic, perceptual, cognitive, and neuroendocrineresponses. Arch Gen Psychiatry 51:199-214
21. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a): Ketamine activates psychosis and alters limbic bloodflow in schizophrenia. NeuroReport 6:869-872
22. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b): Sub-anesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
23. Lieberman JA, Kane JM, Alvir J (1987): Provocative tests with psychostimulant drugs in schizophrenia. Psycho-pharmacology 91:415-433
24. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959): Study of a new schizophrenomimetic drug-ser-nyl. Arch Neurol Psychiatry 81:363-369
25. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997): Ketamine-induced exacerbation of psychotic symptoms and cognitive impairmentin neuroleptic-free schizophrenics. Neuropsychophar-macology 17:41-50
26. Marek GJ, Aghajanian GK (1998): The electrophysiology of prefrontal serotonin systems: Therapeutic implicationsfor mood and psychosis. Biol Psychiatry 44:1118-1127
27. Meltzer HY (1996): Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. Br J Psychiatry168(Suppl 29):23-31
28. Meltzer HY, Matsubara S, Lee J-C (1989): Classification of typical and atypical antipsychotic drugs on the basis ofD-1, D-2 and serotonin2pKivalues. J PharmacolExpTher 251:238-246
29. Moghaddam B (1994): Recent basic findings in support of excitatory amino acid hypothesis of schizophrenia. ProgNeuro-PsychopharmacolBiol Psychiatry 18:859-870
30. Moghaddam B, Adams BW (1998): Reversal of phencycli-dine effects by a group II metabotropic glutamate recep-tor agonist in rats. Science 281:1349-1352
31. Monleon S, D’Aquila P, Parra A, Simon VM, Brain PF, Will-ner P (1995): Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology 117:453-457
32. Moser PC, Moran PM, Frank RA, Kehne JH (1996): Reversal of amphetamine-induced behaviours by MDL 100, 907, aselective 5-HT2Aantagonist. Behav Brain Res 73:163-167
33. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995): Enhancement of immobility in a forced swimming testby subacute or repeated treatment with phencyclidine: Anew model of schizophrenia. Br J Pharmacol 116:2531-2537
34. Noda Y, Mamiya T, Furukawa H, Nabeshima T (1997): Effects of antidepressants on phencyclidine-inducedenhancement of immobility in a forced swimming testin mice. Eur J Pharmacol 324:135-140
35. Nordström A-L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995): Dx, D2and 5-HT2receptor occupancyin relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
36. Olney JW, Farber NB (1995): Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
37. Papp M, Moryl E, Willner P (1996): Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296:129-136
38. Pearlson GD (1981): Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 148:25-33
39. Porsolt RD, Anton G, Blavat N, Jalfre M (1978): Behavioral despair in rats: A new model sensitive to antidepressanttreatments. Eur J Pharmacol 47:379-391
40. Porsolt RD, Bertin A, Jalfre M (1977a): Behavioural despair in mice: A primary screening test for antidepressants.Arch IntPharmacodynTher 229:327-336
41. Porsolt RD, Le Pichon M, Jalfre M (1977b): Depression: A new animal model sensitive to antidepressant treatments. Nature 266:730-732
42. Sams-Dodd F (1998): Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats.Neuropsychopharmacology 19:18-25
43. Schmidt CJ, Fadayel GM (1995): The selective 5-HT2Areceptor antagonist MDL 100, 907 increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol273:273-279
44. Shapiro LE, Schlemmer RF, Young JF, Fleming CK, Davis JM (1996): Antagonism of amphetamine-induced behav-ioral changes in selected members of a primate socialcolony by the selective 5-HT2Aantagonist MDL 100, 907.SocNeurosciAbstr 22:179
45. Shapiro LE, Schlemmer RF, Young JF, Tonkovich LA, Davis JM (1995): Acute administration of (±)DOI and MDL100907 to selected members of a primate social colony:Insights into 5-HT2A-mediated behavioural changes inmonkeys. Schizophr Res 15:164
46. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993):Characterization of the 5-HT2receptor antagonist MDL100907 as a putative atypical antipsychotic: Behavioralelectrophysiological and neurochemical studies. JPharm ExpTher 266:684-691
47. Willins DL, Deutch AY, Roth BL (1997): Serotonin 5-HT2Areceptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82
48. Willner P, Towell A, Sampson D, Muscat R, Sopholeous S (1987): Reduction of sucrose preference by chronic mildstress and its restoration by a tricyclic antidepressant.Psychopharmacology 93:358-364